About LumaBridge
LumaBridge is a company based in San Antonio (United States) founded in 2000 by George Peoples was acquired by Avance Clinical in January 2026.. LumaBridge offers products and services including Clinical Trial Consultation, Regulatory Affairs Services, and Data Management Services. LumaBridge operates in a competitive market with competitors including Orakl Oncology, Oncodesign, Lytica Therapeutics, Orange Grove Bio LLC and Axios Biosciences, among others.
- Headquarter San Antonio, United States
- Founders George Peoples
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Lumabridge, Llc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Latest Funding Round
-
Investors
Avance Clinical
& 1 more
-
Employee Count
Employee Count
-
Acquired by
Avance Clinical
(Jan 07, 2026)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of LumaBridge
LumaBridge offers a comprehensive portfolio of products and services, including Clinical Trial Consultation, Regulatory Affairs Services, and Data Management Services. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Guides biopharma on trial design and development strategies.
Assists in navigating FDA procedures and regulatory requirements.
Handles clinical data management and biostatistics for trials.
Unlock access to complete
Funding Insights of LumaBridge
- Total Funding Total Funding
- Total Rounds 1
- Last Round Last Round
- First Round First Round
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2022 | Amount | Seed - LumaBridge | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in LumaBridge
LumaBridge has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Avance Clinical and Summit Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Summit Partners is recognized as a growth equity investment firm.
|
Founded Year | Domain | Location | |
|
Clinical development services are provided to pharmaceutical clients worldwide.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by LumaBridge
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - LumaBridge
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Lumabridge Comparisons
Competitors of LumaBridge
LumaBridge operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Orakl Oncology, Oncodesign, Lytica Therapeutics, Orange Grove Bio LLC and Axios Biosciences, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Orakl Oncology is a precision oncology start-up that enables the emergence of rare oncology by connecting patient tumors to the world's 3rd best cancer center.
|
|
| domain | founded_year | HQ Location |
Preclinical assessment services for anti-cancer therapies are provided.
|
|
| domain | founded_year | HQ Location |
Therapeutic drugs are developed for medical applications.
|
|
| domain | founded_year | HQ Location |
Provider of preclinical development services
|
|
| domain | founded_year | HQ Location |
Creates innovative platforms for anti-cancer drug development.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Lumabridge
Frequently Asked Questions about LumaBridge
When was LumaBridge founded?
LumaBridge was founded in 2000 and raised its 1st funding round 22 years after it was founded.
Where is LumaBridge located?
LumaBridge is headquartered in San Antonio, United States. It is registered at San Antonio, Texas, United States.
Who is the current CEO of LumaBridge?
Dave Boyle is the current CEO of LumaBridge.
What does LumaBridge do?
LumaBridge was founded in 2000 and is based in San Antonio, United States. Oncology-focused clinical research organization services are offered, including clinical trial design and execution for emerging biopharma companies. Regulatory affairs and data management support are provided as part of strategic development partnerships. Academic, scientific, and commercial perspectives are integrated to advance immunotherapies in the oncology sector.
Who are the top competitors of LumaBridge?
LumaBridge's top competitors include Oncodesign, Orakl Oncology and Lytica Therapeutics.
What products or services does LumaBridge offer?
LumaBridge offers Clinical Trial Consultation, Regulatory Affairs Services, and Data Management Services.
Who are LumaBridge's investors?
LumaBridge has 2 investors. Key investors include Avance Clinical, and Summit Partners.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.